Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory Phase 3 Study of BBI-4000 (sofpironium bromide) Gel in Primary Axillary Hyperhidrosis
jRCT2080223891Phase 3Completed
- Sponsor
- KAKEN PHARMACEUTICAL CO., LTD.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential axillary hyperhidrosis comparing BBI-4000 (sofpironium bromide) 5% gel with Vehicle gel (BBI-4000 0%) (2 arms). Started May 2018; status: completed.
02
Drugs
sofpironium
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on jRCT2080223891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223891.